Can I Take Folate with Fosamax (Alendronate)?

The Short Answer: No Direct Interaction, But Timing Still Matters

Folate and alendronate do not compete for the same receptors, do not share metabolic pathways in the liver, and do not alter each other's pharmacodynamics. Published interaction databases including the Natural Medicines Database and standard clinical review sources list no recognized pharmacokinetic interaction between folic acid or methylfolate and bisphosphonates as a drug class.

The real concern is mechanical, not biochemical. Alendronate has notoriously poor oral bioavailability of roughly 0.6 to 0.7% under ideal fasting conditions, and that number drops sharply if you take it with anything other than plain tap water. Coffee, juice, mineral water, food, calcium supplements, iron, and most other nutrients can cut absorption by 60% or more. A folate tablet taken at the same time as alendronate is not chemically dangerous, but it triggers the swallowing reflex, may prompt you to drink juice or coffee alongside it, and introduces a tablet matrix that could slow gastric emptying and reduce the drug's window for absorption.

The bottom line for your morning routine: alendronate goes first, with a full 8-oz glass of plain water, and everything else waits at least 30 minutes.

Why Alendronate Absorption Is So Fragile

Alendronate is absorbed in the proximal small intestine through passive, paracellular transport. The drug carries two phosphonate groups that chelate divalent cations, meaning any mineral-containing food, drink, or supplement in the stomach competes directly for the drug. Even antacid-containing formulations or calcium-fortified juice reduce alendronate bioavailability by up to 60%.

The FDA prescribing label is explicit: take alendronate at least 30 minutes before the first food, beverage, or medication of the day. Some clinicians extend this to 60 minutes for women who have upper-GI sensitivity or who take supplements with calcium, magnesium, or iron.

Where Folate Fits In

Folate is a water-soluble B vitamin absorbed primarily in the jejunum via a proton-coupled folate transporter. It does not chelate divalent cations the way bisphosphonates do, and it does not inhibit the same transporters alendronate depends on. When taken 30 to 60 minutes after alendronate, the two never share the same absorption window. There is no pharmacodynamic overlap at the tissue level either: alendronate acts on osteoclasts via the mevalonate pathway, while folate participates in one-carbon metabolism and DNA methylation.

Why Women on Fosamax Often Need Folate Anyway

Women taking alendronate are most commonly postmenopausal, but a meaningful proportion are perimenopausal, have glucocorticoid-induced bone loss, or are premenopausal women with conditions such as PCOS, early surgical menopause, or rheumatologic disease requiring long-term steroids. Folate needs vary across these groups.

Postmenopausal Women

After menopause, dietary folate intake often drops below recommended levels because overall caloric intake decreases. Elevated homocysteine, a marker partly regulated by B-vitamin status including folate, has been associated with increased fracture risk independent of bone mineral density in observational data. A 2004 study in the New England Journal of Medicine found that women in the highest quartile of plasma homocysteine had a relative risk of hip fracture of 1.9 compared to those in the lowest quartile. Folate helps clear homocysteine through remethylation, which is why maintaining adequate folate status may support bone health beyond what alendronate alone provides, though this relationship is not yet proven in randomized controlled trials and should not replace standard osteoporosis therapy.

Perimenopausal Women

The perimenopause transition typically spans 4 to 8 years, during which estrogen fluctuations accelerate bone turnover. If you are in this stage and your clinician has started alendronate due to low bone density or a fragility fracture, you are likely still menstruating intermittently, which means folate remains relevant for cardiovascular methylation support and, if pregnancy is possible, for neural tube defect prevention.

Reproductive-Age Women with Bone Loss

Premenopausal women sometimes receive alendronate for glucocorticoid-induced osteoporosis or conditions like anorexia-related bone loss. This group has the most complex calculus, because alendronate carries specific risks during pregnancy (discussed in detail below). Folate supplementation at 400 to 800 mcg DFE per day is recommended by the USPSTF for all women of reproductive potential.

MTHFR, Folate Metabolism, and What It Means for You

MTHFR (methylenetetrahydrofolate reductase) is an enzyme that converts dietary folic acid and food folate into 5-methyltetrahydrofolate, the active circulating form the body uses for methylation reactions. Roughly 10 to 15% of people of Northern European descent are homozygous for the C677T variant, which reduces enzyme activity by approximately 70% in homozygous carriers and 35% in heterozygous carriers.

What MTHFR Means for Folate Dosing

Women with the homozygous C677T variant convert folic acid less efficiently. Standard folic acid supplements (the synthetic, oxidized form in most multivitamins) require the MTHFR enzyme to become metabolically active. A practical framework used in clinical nutrition practice, though not yet codified in a single guideline, is:

• Standard folic acid (400-800 mcg): appropriate for women without known MTHFR variants
• L-methylfolate (the pre-converted form, sold as Metafolin, Deplin, or generic methylfolate): may be preferred for MTHFR C677T homozygotes because it bypasses the conversion step
• Folinic acid (5-formyltetrahydrofolate): another bioavailable form that does not require MTHFR conversion

Neither methylfolate nor folinic acid interacts with alendronate differently than standard folic acid does. The 30-minute separation rule applies equally to all folate forms.

MTHFR and Homocysteine in Bone Health

Elevated homocysteine concentrations, which occur more often in MTHFR C677T homozygotes, may contribute to collagen cross-link disruption in bone matrix. A 2005 analysis in the Journal of Bone and Mineral Research found that homocysteine directly inhibits the activity of lysyl oxidase, an enzyme critical for collagen maturation in bone. This mechanistic finding supports the clinical observation linking high homocysteine to fracture risk, though again, no randomized trial has proven that lowering homocysteine with B vitamins reduces fracture incidence in women already on bisphosphonates.

Folate and Anticonvulsants: A Special Case for Women with Epilepsy

Some women take alendronate not only for postmenopausal bone loss but because long-term anticonvulsant therapy depletes bone mineral density. Anticonvulsants including phenytoin, carbamazepine, and valproate induce hepatic CYP450 enzymes that accelerate folate degradation, and valproate specifically inhibits dihydrofolate reductase, reducing folate bioavailability further. Women in this situation are at risk of both anticonvulsant-induced osteoporosis and folate deficiency simultaneously.

For this group, clinicians typically prescribe supplemental folate at 1 to 5 mg per day depending on the specific anticonvulsant regimen, with some ACOG guidance recommending 4 to 5 mg daily for women on folate-depleting anticonvulsants who are pregnant or planning pregnancy. Alendronate and high-dose folate coexist safely at the clinical level; the 30-minute separation window remains the only practical instruction.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Alendronate is contraindicated during pregnancy. This is a required section, and the contraindication is unambiguous.

Pregnancy Risk

Bisphosphonates incorporate into bone mineral and are released slowly over years after a course of treatment. Animal studies show fetal skeletal hypocalcemia and perinatal death at doses that produce systemic exposures comparable to clinical doses in humans. The FDA prescribing label for alendronate carries a formal contraindication in pregnancy, and ACOG has noted the absence of adequate human safety data in pregnant women.

Because alendronate can persist in bone for years to over a decade after discontinuation, any woman of reproductive potential starting alendronate should have an explicit conversation with her clinician about pregnancy planning. The current standard, based on expert opinion rather than definitive trial data (an evidence gap worth naming), is to discontinue alendronate at least 3 to 6 months before a planned conception and ideally longer if the cumulative dose has been high.

Folate During Pregnancy

Folate, by contrast, is essential in pregnancy. The USPSTF recommends 400 to 800 mcg of folic acid daily for all women capable of becoming pregnant, starting before conception and continuing through at least the first trimester. Women who have previously had a neural tube defect-affected pregnancy should take 4 mg daily starting 1 month before conception per ACOG guidance.

The practical intersection: if you are stopping alendronate to plan a pregnancy, you should already be on adequate folate. The two drugs do not interact pharmacologically in this scenario, because you will no longer be taking alendronate.

Lactation

Alendronate has not been studied in breastfeeding women, and given its mechanism and skeletal storage, most clinicians advise against use during lactation. Folate is excreted into breast milk and is safe and recommended during lactation, with lactating women needing approximately 500 mcg DFE per day.

Contraception Requirement

Because of the prolonged skeletal retention of alendronate and its teratogenic potential in animal studies, any woman of reproductive age taking alendronate should use effective contraception. This recommendation is based on expert consensus rather than a formal FDA-labeled requirement, but it reflects standard-of-care practice. Discuss your specific contraceptive options with your prescriber, particularly if you have PCOS or a history of irregular cycles that complicate cycle-based methods.

Who This Is Right For, and Who Should Take Extra Care

Women This Combination Suits Well

• Postmenopausal women on weekly alendronate who want to support homocysteine metabolism and cover nutritional folate gaps
• Perimenopausal women with early bone loss who are also taking folate for cardiovascular or general nutritional reasons
• Women with MTHFR variants who need methylfolate supplementation alongside bone-protective therapy
• Women on long-term glucocorticoids for autoimmune conditions who have been started on alendronate and need folate for general B-vitamin support

Women Who Need a More Careful Conversation

• Reproductive-age women on alendronate for premenopausal osteoporosis: you need reliable contraception and a clear plan for if and when you want to conceive
• Women on anticonvulsants: your folate dose may need to be significantly higher than the standard 400 to 800 mcg range, and your bone density deserves monitoring on both fronts
• Women with a history of upper-GI conditions such as Barrett's esophagus or active esophageal disease: alendronate already carries esophageal irritation risk, and the dosing instructions become even more important to follow precisely

How to Take Both Safely: A Step-by-Step Morning Protocol

Getting the timing right is the central clinical instruction for this combination. Here is a concrete sequence:

1. Wake up. Before coffee, tea, juice, or breakfast.
2. Take alendronate with a full 8-oz (240 mL) glass of plain tap or still water. No sparkling water, no mineral water.
3. Remain upright (sitting or standing) for at least 30 minutes. Do not lie down. This reduces esophageal exposure.
4. After 30 minutes have passed and you have eaten or drunk something, take your folate supplement with or without food. Folate absorption is not significantly affected by food.
5. If you miss the morning window for alendronate (for example, you already drank coffee), skip that day's dose and take it the following morning. Do not take it later in the same day.

For women on weekly alendronate (the most common regimen at 70 mg once weekly), the folate routine continues every day regardless of which day you take alendronate.

Monitoring: What Labs and Follow-Up Look Like

Your clinician may check the following over the course of treatment:

• Bone mineral density (DXA scan): Typically repeated every 1 to 2 years after initiating therapy, then less frequently once stable
• Serum folate and red blood cell folate: Useful if you have MTHFR variants, are on anticonvulsants, or have GI conditions that impair absorption
• Plasma homocysteine: Not a routine screen but relevant if your clinician is evaluating cardiovascular or fracture risk beyond standard bone density markers
• Serum calcium, vitamin D, and parathyroid hormone: Standard companions to bisphosphonate therapy; calcium and vitamin D must be adequate for alendronate to work, and supplemental calcium should be timed away from the alendronate dose

The Endocrine Society Clinical Practice Guideline on osteoporosis in postmenopausal women notes that adequate calcium (1,000-1,200 mg per day from food and supplements combined) and vitamin D (600-800 IU per day, often higher in practice) are prerequisites for bisphosphonate therapy. Neither calcium nor vitamin D should be taken within 30 to 60 minutes of alendronate.

The Evidence Gap You Deserve to Know About

Women have been underrepresented in nutrition-pharmacology interaction studies. The data supporting the homocysteine-fracture link is largely observational, drawn from cohort studies rather than intervention trials. No randomized controlled trial has specifically tested whether correcting folate status in women on alendronate improves fracture outcomes beyond the bisphosphonate effect alone.

The landmark Fracture Intervention Trial (FIT), which established alendronate's efficacy in reducing vertebral and hip fractures, enrolled postmenopausal women exclusively, which is a genuine strength for this population. Folate status was not measured or controlled in FIT, so any combination between adequate folate and alendronate therapy remains an open research question.

What is established: alendronate reduces vertebral fracture risk by approximately 47% over 3 years in women with prior fracture, and folate at recommended doses is safe, inexpensive, and broadly indicated for most women. Taking both, with proper timing, is reasonable and well-supported by existing safety data even where direct efficacy data for the combination is lacking.

As WomanRx reviewer Rachel Goldberg, MD, notes: "The folate-alendronate question comes up often in postmenopausal women who are managing multiple supplements. There is no pharmacological reason to avoid folate alongside a bisphosphonate. The only instruction I give patients is the same one I give for every other supplement: alendronate goes first, alone, with plain water, and nothing else for at least 30 minutes. After that, take your folate whenever works for you."